RxDoctor Payments Data

Rochelle Goldberg, MD

Pulmonary Disease · Wynnewood, PANPI 1649205386

Payments from drug & device makers

$15,705in general payments, 2019–2025

Across 96 payments — averaging $163.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Jazz Pharmaceuticals Inc.$10K
  • Harmony Biosciences LLC$5K
  • Regeneron Healthcare Solutions, Inc.$240
  • Axsome Therapeutics, Inc.$222
  • Avadel CNS Pharmaceuticals, LLC$202
  • ZOLL Respicardia, Inc.$132
  • plus $493 from 15 others

What the payments were for

  • Speaking & faculty fees$9,38080%
  • Food & beverage$2,18519%
  • Education$1401%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,705 in reported general payments places this provider in the 80th percentile of 703 pulmonary disease providers in Pennsylvania.

See all pulmonary disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$78,871
Medicare patients
510
Services billed
658

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XywavSodium,calcium,mag,pot Oxybate26$455,913
Sodium Oxybate22$300,905
Breo ElliptaFluticasone/Vilanterol11$7,124
DayvigoLemborexant14$4,800
Armodafinil64$3,788
Dextroamphetamine Sulfate ErDextroamphetamine Sulfate17$2,996
Modafinil56$2,568
Zolpidem Tartrate62$1,079
Temazepam34$955
Methylphenidate ErMethylphenidate Hcl15$879
Ropinirole Hcl41$727
Gabapentin83$615
Eszopiclone12$583
Clonazepam97$532
Pramipexole DihydrochloridePramipexole Di-Hcl66$461

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBreo Ellipta$20$7,12411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 703 pulmonary disease providers in Pennsylvania.

Other pulmonary disease in Wynnewood

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →